Medical News

RSS

Gilead enters agreement for Pharmasset acquisition

Gilead Sciences, Inc. and Pharmasset, Inc. announced today that the companies have signed a definitive agreement under which Gilead will acquire Pharmasset for $137 per share in cash.

21 Nov 2011

ZEVALIN treatment for Non-Hodgkin lymphoma becomes simpler with removal of bioscan requirement

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, received approval from the U.S. Food and Drug Administration (FDA) on November 18, 2011 to remove the pre-treatment biodistribution evaluation requirement using Indium-111 ZEVALIN imaging dose followed by a gamma scan before administering the ZEVALIN therapeutic dose.

21 Nov 2011

Multi-center cabozantinib trial for hormone receptor-positive breast cancer with bone metastases initiated

Exelixis, Inc. today announced the initiation of an investigator-sponsored trial of cabozantinib in women with hormone receptor-positive breast cancer with bone metastases.

21 Nov 2011

Health Management enters into new credit facilities and closes $875M Notes offering

Health Management Associates, Inc. announced today that it entered into new credit facilities, including a $500 million senior secured revolving credit facility, a $725 million senior secured term loan A with a five year term and a $1.4 billion senior secured term loan B with a seven year term.

21 Nov 2011

Positive preliminary results from Alnylam's ALN-TTR01 Phase I clinical trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive preliminary results from its Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).

21 Nov 2011

Adeona to develop and commercialize DNA-based therapeutic for PAH using Intrexon technology

Adeona Pharmaceuticals, Inc., and the Human Therapeutics Division of Intrexon Corporation, announced today the formation of a global exclusive channel collaboration through which Adeona intends to develop and commercialize a DNA-based therapeutic using Intrexon's UltraVector platform and RheoSwitch Therapeutic System for the treatment of pulmonary arterial hypertension (PAH).

21 Nov 2011

Selecta commences SEL-068 Phase 1 clinical trial for smoking cessation and relapse prevention

Selecta Biosciences, Inc., a biopharmaceutical company developing a new class of synthetic vaccines and immunotherapies, today announced that it has initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacodynamic profile of SEL-068, a nicotine vaccine candidate for smoking cessation and relapse prevention.

21 Nov 2011

FDA grants HDE marketing approval for BSD-2000 Hyperthermia System to treat cervical cancer

BSD Medical Corporation, a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that the Company has obtained Humanitarian Device Exemption (HDE) marketing approval for the BSD-2000 Hyperthermia System (BSD-2000) from the U.S. Food and Drug Administration.

21 Nov 2011

InferX third quarter gross profit increases 75% to $283,806

InferX Corporation, a market leader in next generation Predictive Analytics products and solutions for the defense, healthcare and intelligence communities, today announced financial results for the third quarter of fiscal year 2011, which ended September 30, 2011.

21 Nov 2011

Cancer Research UK initiates recruitment for Stratified Medicine Programme

Cancer Research UK has started recruiting patients for a pioneering initiative to demonstrate how genetic tests could be used within the NHS to help match cancer patients to the most appropriate treatment, while building a database of information for research into new targeted therapies.

21 Nov 2011

ShangPharma third quarter net revenues increase 24.7% to $28.8 million

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced its unaudited financial results for the quarter ended September 30, 2011.

21 Nov 2011

Comprehensive Care nine month revenues increase 212% to $54,039,000

Comprehensive Care Corporation, a leading behavioral health, substance abuse and psychotropic pharmacy management services provider for managed care companies throughout the U.S., is pleased to announce that its revenues for the nine months ended September 30, 2011 increased 212 percent to $54,039,000 compared to $17,344,000 for the same period in 2010.

21 Nov 2011

$GE Healthcare, Neste Jacobs enter alliance to increase self-sufficiency in blood plasma fractionation$

GE Healthcare, Neste Jacobs enter alliance to increase self-sufficiency in blood plasma fractionation

GE Healthcare, the healthcare business of GE and Neste Jacobs, a leading global expert in plasma fractionation plant engineering design and construction, announced today that the companies have formed a strategic alliance to assist countries worldwide to become self-sufficient in the manufacture of blood plasma products.

21 Nov 2011

ICON selected as CRO for Tasly's Dantonic pill global Phase III studies for chronic stable angina pectoris

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been selected by Tasly Pharmaceuticals for the company's global Phase III T89 trial. T89, also known as Dantonic pill, aims to become the first traditional Chinese medicine to receive FDA approval in the United States.

21 Nov 2011

New blood pressure remote monitoring program for Stamford employees, families

Stamford Hospital has launched a new blood pressure remote monitoring program for its employees and their families in order to detect risk factors for heart disease while helping to improve their overall health.

21 Nov 2011

OTS to market and disribute RaySearch's RayStation in South Korea

...

21 Nov 2011

EMA validates Pfizer's Market Authorisation Application for tofacitinib to treat rheumatoid arthritis

Pfizer Inc. announced today that its Market Authorisation Application for tofacitinib (development code CP-690,550), a novel, oral JAK inhibitor being studied for the treatment of moderate-to-severe active rheumatoid arthritis (RA), has been validated by the European Medicines Agency (EMA).

21 Nov 2011

South Asian cardiac patients three times as likely to require repeat treatment following PCI

South Asian patients with coronary artery disease were almost three times as likely to be readmitted to hospital for further interventional treatment to arterial plaque than their White European counterparts, according to research in the December issue of IJCP, the International Journal of Clinical Practice.

21 Nov 2011

New method for counting molecules

Researchers at the Swedish medical university Karolinska Institutet have developed a new method for counting molecules.

21 Nov 2011

Convergence commences CNV2197944 multiple ascending dose Phase I study for chronic pain

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announces that the multiple ascending dose Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated.

21 Nov 2011

Medical News

Gilead enters agreement for Pharmasset acquisition

ZEVALIN treatment for Non-Hodgkin lymphoma becomes simpler with removal of bioscan requirement

Multi-center cabozantinib trial for hormone receptor-positive breast cancer with bone metastases initiated

Health Management enters into new credit facilities and closes $875M Notes offering

Positive preliminary results from Alnylam's ALN-TTR01 Phase I clinical trial for TTR-mediated amyloidosis

Adeona to develop and commercialize DNA-based therapeutic for PAH using Intrexon technology

Selecta commences SEL-068 Phase 1 clinical trial for smoking cessation and relapse prevention

FDA grants HDE marketing approval for BSD-2000 Hyperthermia System to treat cervical cancer

InferX third quarter gross profit increases 75% to $283,806

Cancer Research UK initiates recruitment for Stratified Medicine Programme

ShangPharma third quarter net revenues increase 24.7% to $28.8 million

Comprehensive Care nine month revenues increase 212% to $54,039,000

GE Healthcare, Neste Jacobs enter alliance to increase self-sufficiency in blood plasma fractionation

ICON selected as CRO for Tasly's Dantonic pill global Phase III studies for chronic stable angina pectoris

New blood pressure remote monitoring program for Stamford employees, families

OTS to market and disribute RaySearch's RayStation in South Korea

EMA validates Pfizer's Market Authorisation Application for tofacitinib to treat rheumatoid arthritis

South Asian cardiac patients three times as likely to require repeat treatment following PCI

New method for counting molecules

Convergence commences CNV2197944 multiple ascending dose Phase I study for chronic pain

Advancing Menopause Care: Non-Hormonal Treatments for Vasomotor Symptoms

Building quality into drug development for safer, faster medicines

How Pulp Fixin Is Turning Paper into High-Performance Sustainable Labware

Latest News